Search Result

Isoforms Recommended:	Aurora B

Results for "

Aurora B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aurora Kinase (99) AAK1 (1) Akt (4) Antibiotic (7) Apoptosis (26) Autophagy (10) Bacterial (6) Bcl-2 Family (1) Bcr-Abl (6) c-Fms (1) c-Kit (1) CDK (5) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (2) EGFR (2) FAK (2) FGFR (1) FLT3 (7) GSK-3 (7) HDAC (2) IGF-1R (2) Influenza Virus (2) Isotope-Labeled Compounds (1) JAK (6) Kinesin (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitosis (3) Mps1 (1) NEKs (3) Parasite (2) PDGFR (3) PERK (1) Phosphodiesterase (PDE) (1) PI3K (1) Polo-like Kinase (PLK) (2) PROTACs (4) Reactive Oxygen Species (ROS) (2) Reference Standards (13) Src (1) STAT (3) Syk (1) TAM Receptor (1) Tie (1) ULK (1) VEGFR (6)
By Research Areas:	Cancer (103) Infection (7) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Alkynes (2)

108

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

GMP Molecules

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0712B

Ceftriaxone sodium salt 15+ Cited Publications Ro 13-9904	Antibiotic GSK-3 Bacterial Aurora Kinase	Infection Inflammation/Immunology Cancer
Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis .

HY-B0712

Ceftriaxone 15+ Cited Publications Ro 13-9904 free acid	Bacterial Antibiotic GSK-3 Aurora Kinase	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, *aurora-A* and *aurora-B*, respectively .

HY-10161

Tozasertib 15+ Cited Publications VX 680; MK-0457	Aurora Kinase Autophagy	Cancer
Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with K_is of 0.6, 18, 4.6 nM, respectively.

HY-10127

Barasertib Maximum Cited Publications 25 Publications Verification AZD1152	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .

HY-12054

Hesperadin 10+ Cited Publications	Aurora Kinase Autophagy Influenza Virus Parasite	Cancer
Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC₅₀ of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral .

HY-14711

Reversine 15+ Cited Publications	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC₅₀s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.

HY-10179

Danusertib 5+ Cited Publications PHA-739358	Aurora Kinase Autophagy	Cancer
Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC₅₀ of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-13253

AMG 900 4 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-10126

Barasertib-HQPA 5+ Cited Publications AZD2811; INH-34; AZD1152-HQPA	Aurora Kinase Apoptosis	Cancer
Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells .

HY-70044

GSK-1070916 5 Publications Verification GSK-1070916A	Aurora Kinase Apoptosis	Cancer
GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀**s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-10128

ZM-447439 5+ Cited Publications	Aurora Kinase Apoptosis	Cancer
ZM-447439 is an *aurora* kinase inhibitor with IC₅₀s of 110 and 130 nM for aurora A and B, respectively.

HY-B0712A

Ceftriaxone sodium hydrate 15+ Cited Publications Ro 13-9904 sodium hydrate	Bacterial Antibiotic GSK-3 Aurora Kinase	Infection Cancer
Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .

HY-10558

CYC-116 4 Publications Verification	Aurora Kinase	Cancer
CYC-116 is a potent aurora A and aurora B inhibitor with K_is of 8 and 9 nM, respectively.

HY-12201

TAK-901 5 Publications Verification	Aurora Kinase	Cancer
TAK-901 is a multi-targeted *aurora* inhibitor with IC₅₀s of 21 and 15 nM for aurora A and B, respectively.

HY-12003

SNS-314 mesylate 3 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-137377

TAS-119 1 Publications Verification	Aurora Kinase	Cancer
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC₅₀ of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC₅₀ of 95 nM). TAS-119 has potent antitumor activites .

HY-124526

Chiauranib Ibcasertib; CS2164	PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-10804

CCT 137690 1 Publications Verification	Aurora Kinase Apoptosis	Cancer
CCT 137690 is a potent and orally available *aurora* kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

HY-14574

PF-03814735 2 Publications Verification	Aurora Kinase VEGFR	Cancer
PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and aurora B inhibitor with IC₅₀s of 0.8 and 0.5 nM, respectively.

HY-107419

NU6140 1 Publications Verification	CDK Aurora Kinase	Cancer
NU6140 is a selective CDK2-cyclin A inhibitor (IC₅₀, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC₅₀s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .

HY-145601

Tinengotinib TT 00420	Aurora Kinase FGFR VEGFR	Cancer
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting **Aurora A/B (IC₅₀=1.2-3.3 nM), FGFR1/2/3 (IC₅₀=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R*. Tinengotinib blocks Aurora* kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .

HY-131339

SP-96 2 Publications Verification	Aurora Kinase	Cancer
SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .

HY-122236

UMK57	Mitosis Kinesin Microtubule/Tubulin Aurora Kinase	Cancer
UMK57 is a MCAK activator and kinetochore-microtubule destabilizer. UMK57 enhances MCAK-dependent microtubule depolymerization, increases kinetochore-microtubule turnover, reduces chromosome mis-segregation and lagging chromosomes, and inhibits cancer cell proliferation. UMK57 triggers adaptive resistance in Aurora B cancer cells via reversible Aurora B signaling pathway alterations. UMK57 can be used for the research of solid tumors .

HY-10178

PHA-680632	Aurora Kinase	Cancer
PHA-680632 is an *aurora* kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive *aurora* inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive *aurora* inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-141512

JB170 3 Publications Verification	PROTACs Aurora Kinase	Cancer
JB170 is a potent and highly specific PROTAC-mediated *AURORA-A* (Aurora Kinase) degrader (DC₅₀=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC₅₀=193 nM) over AURORA-B (EC₅₀=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC₅₀s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .

HY-10483

SCH-1473759 hydrochloride	Aurora Kinase	Cancer
SCH-1473759 hydrochloride is an *aurora* inhibitor with IC₅₀s of 4 and 13 nM for aurora A and B, respectively.

HY-12049

CCT129202	Aurora Kinase	Cancer
CCT129202 is an *aurora* kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

HY-171770

dAurAB5	PROTACs Aurora Kinase AAK1 Cyclin G-associated Kinase (GAK) Mps1 FAK	Cancer
dAurAB5 is a dual *Aurora-A* (DC₅₀ = 8.8 nM) and *Aurora-B* (DC₅₀ = 6.1 nM) PROTAC degrader. dAurAB5 induces degradation of *Aurora-A* and *Aurora-B*, reduces N-Myc levels, and decreases viability in IMR32 neuroblastoma cells. dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. dAurAB5 can be used to study cancers such as neuroblastoma. (Pink: TTK ligand 2: HY-168542, Blue: Thalidomide-O-COOH: HY-103597, Black: 6-Aminocaproic acid: HY-B0236) .

HY-132135

(1E)-CFI-400437 dihydrochloride	Polo-like Kinase (PLK)	Cancer
(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .

HY-10482

SCH-1473759	Aurora Kinase	Cancer
SCH-1473759 is an *aurora* inhibitor with IC₅₀s of 4 and 13 nM for aurora A and B, respectively.

HY-103266

TC-A 2317 hydrochloride	Aurora Kinase	Cancer
TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (K_i=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .

HY-171769

dAurAB2	PROTACs Aurora Kinase	Cancer
dAurAB2 is a dual-degrading PROTAC that potently degrades *Aurora-A* and *Aurora-B* with DC₅₀s of 59 nM and 39 nM, respectively. dAurAB2 reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells. dAurAB2 can be used for the study of neuroblastoma. (Pink, Aurora ligand (HY-10804); Blue, E3 ligand: (HY-103597); Black, linker (HY-W105740)) .

HY-126249

AAPK-25	Aurora Kinase Polo-like Kinase (PLK) Apoptosis	Cancer
AAPK-25 is a potent and selective *Aurora/PLK* dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3 ^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM .

HY-B0712R

Ceftriaxone (Standard) Ro 13-9904 free acid (Standard)	Reference Standards Bacterial Antibiotic GSK-3 Aurora Kinase	Infection Inflammation/Immunology Cancer
Ceftriaxone (Standard) is the analytical standard of Ceftriaxone. This product is intended for research and analytical applications. Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].

HY-10127A

Barasertib dihydrochloride AZD1152 dihydrochloride	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152 dihydrochloride), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152 dihydrochloride) induces growth arrest and apoptosis in cancer cells .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-175866

Aurora kinase-IN-8	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-8 is a orally active Aurora kinase inhibitor. Aurora kinase-IN-8 shows IC₅₀ values of 2.8 and 28.1 nM against Aurora A kinase and Aurora B kinase. Aurora kinase-IN-8 can prevent spindle formation, cause G2/M phase arrest, and induce cell apoptosis. Aurora kinase-IN-8 can be used for the research of cancer, such as triple-negative breast cancer .

HY-175525

MS44	PROTACs Aurora Kinase	Cancer
MS44 is a potent aurora kinase B (AURKB PROTAC) degrader (DC₅₀ = 103 nM). MS44 effectively degrades AURKB in a time- and ubiquitin-proteasome system (UPS)-dependent manner and is selective for AURKB over AURKA and AURKC. MS44 effectively inhibits the proliferation in multiple cancer cell lines and potently induces G2/M arrest. MS44 can be used for the study of AURKB-dependent tumors (Pink: Target protein ligand (HY-175526); Blue: E3 ligand (HY-112078); Black: Linker; E3 ligand + Linker (HY-132938)) .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-123610

BRD-7880	Aurora Kinase	Cancer
BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC₅₀ values of 7 nM and 12 nM, respectively .

HY-175526

Aurora kinase ligand-1	Ligands for Target Protein for PROTAC Aurora Kinase	Cancer
Aurora kinase ligand-1 (Compound I-4) is an Aurora kinase B (AURKB) PROTAC ligand. Aurora kinase ligand-1 can be conjugated with E3 ligase Ligand (HY-112078) and linker to synthesize AURKB PROTAC degrader MS44 (HY-175525). MS44 can be used for cancer research .

HY-12054A

Hesperadin hydrochloride	Aurora Kinase Autophagy Influenza Virus Parasite	Cancer
Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC₅₀ of 250 nM .

HY-B0712S1

Ceftriaxone-13C2,d3 triethylammonium salt Ro 13-9904-13C2,d32 triethylammonium salt	Antibiotic Aurora Kinase GSK-3 Bacterial Isotope-Labeled Compounds	Infection Inflammation/Immunology Cancer
Ceftriaxone-13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3737

Derrone	Infection Monophenols Flavonoids Phenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Isoflavones Source Classification	Aurora Kinase PERK Reactive Oxygen Species (ROS)
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC₅₀ values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .

HY-N3634

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N1168

Tenacigenin B	Araceae Cardiacglycosides Plants Alocasia cucullata (Lour.) Schott Steroids Source Classification	Aurora Kinase
Tenacigenin B is a steroid that can be isolated from the genus Alocasia. Tenacigenin B has anti-tumor effects on lymphoma via regulation of *Aurora-A* .

HY-N12436

11α-O-Tigloyl-12β-O-acetyltenacigenin B	Structural Classification Marsdenia tenacissima (Roxb.) Moon Asclepiadaceae Plants Steroids Source Classification	Aurora Kinase
11α-O-Tigloyl-12β-O-acetyltenacigenin B is an ester derivative of Tenacigenin B (HY-N1168), which is isolated from Garcinia cambogia (MTC). Tenacigenin B modulates the antitumor effects of Aurora-A in lymphoma.

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704867

	AURORA B Protein, Human (Active, sf9, GST) AURKB; AIK2; AIM1; ARK2; AurB; IPL1; AIM-1; STK12	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0712S1

Ceftriaxone-13C2,d3 triethylammonium salt

Ceftriaxone-13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .

Host:	Mouse (2) Rabbit (4)
Reactivity:	Human (6)
Application:	IHC-P (4) ICC/IF (4) IF-Tissue (1) IP (3) IHC-F (1) WB (4) FC (2) ELISA (1)
Isotype:	IgG (2) IgG1 (2) IgG/Kappa (1)
Conjugation:	Non-conjugated (6)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80562

	Aurora B Antibody (YA594) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IP	Human
	Aurora B Antibody (YA594) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

HY-P86439

	Aurora B Antibody (YA6131) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IHC-P, ICC/IF, IP, ELISA	Human
	Aurora B Antibody (YA6131) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

HY-P85045

	Aurora B Antibody (YA4737) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue	Human
	Aurora B Antibody (YA4737) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Aurora B.

HY-P80562A

	Aurora B Antibody (YA594)(PBS only) AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IP	Human
	Aurora B Antibody (YA594) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

HY-P87277

	INCENP Antibody (YA6960) binds and activates Aurora B and C in vivo and in vitro antibody; Chromosomal passenger protein antibody; INCE_HUMAN antibody; INCENP antibody; Inner centromere protein antibody; Inner centromere protein antigens 135/155kDa antibody; Inner centromere protein antigens 135kD 155kD antibody; Inner centromere protein INCENP antibody	ICC/IF, IHC-P, FC	Human
	INCENP Antibody (YA6960) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to INCENP.

HY-P87277A

	INCENP Antibody (YA6960)(PBS only) binds and activates Aurora B and C in vivo and in vitro antibody; Chromosomal passenger protein antibody; INCE_HUMAN antibody; INCENP antibody; Inner centromere protein antibody; Inner centromere protein antigens 135/155kDa antibody; Inner centromere protein antigens 135kD 155kD antibody; Inner centromere protein INCENP antibody	ICC/IF, IHC-P, FC	Human
	INCENP Antibody (YA6960) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to INCENP.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70044G

GSK-1070916 GSK-1070916A	Apoptosis Aurora Kinase	Cancer
GSK-1070916 (GMP) is GSK-1070916 (HY-70044) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks